Ate van der Gaast

16.5k citations

132 papers · 4.7k · 2 hit papers · h-index 41

Impact in

Surgery top 0.5%
- Esophageal Cancer Research and Treatment
- Esophageal and GI Pathology
Oncology top 2%
- Drug Transport and Resistance Mechanisms
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Research Studies
- Cancer Diagnosis and Treatment

Papers in

Surgery 77
- Esophageal Cancer Research and Treatment 63
- Esophageal and GI Pathology 17
Pulmonary and Respiratory Medicine 41
- Gastric Cancer Management and Outcomes 29
- Lung Cancer Treatments and Mutations 12
- Lung Cancer Diagnosis and Treatment 9

Co-authors: Jaap Verweij (27 shared papers)Ewout W. Steyerberg (25 shared papers)Mark I. van Berge Henegouwen (16 shared papers)G. Stoter (19 shared papers)Hugo W. Tilanus (17 shared papers)Peter D. Siersema (20 shared papers)Ferry A.L.M. Eskens (14 shared papers)Pieter van Hagen (7 shared papers)
Journals: Journal of Clinical Oncology (14 papers)British Journal of Cancer (13 papers)European Journal of Cancer (10 papers)Annals of Oncology (9 papers)Cancer Chemotherapy and Pharmacology (7 papers)
Partner nations: Netherlands United States Belgium

In The Last Decade

Ate van der Gaast

127 papers receiving 4.6k citations

Ate van der Gaast's Hit Papers

align trajectories log scale

Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study) 2021 · 179 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2021 Journal of Clinical Oncology
2014 Journal of Clinical Oncology

Peers

Countries citing papers authored by Ate van der Gaast

Since Specialization

Citations

This map shows the geographic impact of Ate van der Gaast's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ate van der Gaast with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ate van der Gaast more than expected).

Fields of papers citing papers by Ate van der Gaast

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ate van der Gaast. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ate van der Gaast. The network helps show where Ate van der Gaast may publish in the future.

Co-authors

The 25 scholars most cited alongside Ate van der Gaast, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ate van der Gaast Line = papers co-authored together Ate van der Gaast links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 132 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Patterns of Recurrence After Surgery Alone Versus Preoperative Chemoradiotherapy and Surgery in the CROSS Trials Journal of Clinical Oncology ·Vera Oppedijk, Ate van der Gaast, J. Jan B. van Lanschot, Pieter van Hagen, Rob van Os, Caroline M. van Rij, Maurice J.C. van der Sangen, Jannet C. Beukema, Heidi Rütten, Patty H. Spruit, Janny G. Reinders, Dick J. Richel, Mark I. van Berge Henegouwen, Maarten C.C.M. Hulshof Hit paper breakdown →	2014	356
2	Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study) Journal of Clinical Oncology ·Maarten C.C.M. Hulshof, Elisabeth D. Geijsen, Tom Rozema, Vera Oppedijk, Jeroen Buijsen, Karen J. Neelis, Joost J. Nuyttens, Maurice J.C. van der Sangen, Paul M. Jeene, Jannie G. Reinders, Mark I. van Berge Henegouwen, Adriana Thano, Jeanin E. van Hooft, Hanneke W. M. van Laarhoven, Ate van der Gaast Hit paper breakdown →	2021	179
3	Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: Long-term results of a randomized controlled trial BMC Cancer ·Jurjen J. Boonstra, Tjebbe C. Kok, Bas P. L. Wijnhoven, Mark van Heijl, Mark I. van Berge Henegouwen, Fiebo JW ten Kate, Peter D. Siersema, Winand N.M. Dinjens, Jan JB van Lanschot, Hugo W. Tilanus, Ate van der Gaast	2011	136
4	Lymph Node Retrieval During Esophagectomy With and Without Neoadjuvant Chemoradiotherapy Annals of Surgery ·Aaldert K. Talsma, Joël Shapiro, Caspar W. N. Looman, Pieter van Hagen, Ewout W. Steyerberg, Ate van der Gaast, Mark I. van Berge Henegouwen, Bas P. L. Wijnhoven, J. Jan B. van Lanschot	2014	124
5	Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS) BMC Surgery ·Mark van Heijl, JJB van Lanschot, Linetta B. Koppert, Mark I. van Berge Henegouwen, Karin Müller, Ewout W. Steyerberg, Herman van Dekken, (unknown), HW Tilanus, D. J. Richel, O.R. Busch, JF Bartelsman, C. C. E. Koning, G. J. A. Offerhaus, Ate van der Gaast	2008	103
6	Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study British Journal of Cancer ·E. van Meerten, Karin Müller, Hugo W. Tilanus, Peter D. Siersema, W M H Eijkenboom, Herman van Dekken, T.C.K. Tran, Ate van der Gaast	2006	102
7	Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1 British Journal of Cancer ·Ate van der Gaast, CHH Schoenmakers, TC Kok, BG Blijenberg, Freddy Cornillie, T. A. W. Splinter	1994	100
8	Causes and Treatment of Recurrent Dysphagia after Self-Expanding Metal Stent Placement for Palliation of Esophageal Carcinoma Endoscopy ·Marjolein Y.V. Homs, Ewout W. Steyerberg, Ernst J. Kuipers, Ate van der Gaast, Jelle Haringsma, M. van Blankenstein, PD Siersema	2004	95
9	A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors Cancer Chemotherapy and Pharmacology ·A. S. T. Planting, Pieter Sonneveld, Ate van der Gaast, Alex Sparreboom, M.E.L. van der Burg, Gregorius P. M. Luyten, K. De Leeuw, M de Boer-Dennert, Paul Wissel, Roxanne C. Jewell, Elaine Paul, Norman Purvis, Jaap Verweij	2004	90
10	The potential of statins as part of anti-cancer treatment European Journal of Cancer ·Stefan Sleijfer, Ate van der Gaast, André Planting, G. Stoter, Jaap Verweij	2005	90
11	Fluorodeoxyglucose Positron Emission Tomography for Evaluating Early Response During Neoadjuvant Chemoradiotherapy in Patients With Potentially Curable Esophageal Cancer Annals of Surgery ·Mark van Heijl, Jikke M.T. Omloo, Mark I. van Berge Henegouwen, Otto S. Hoekstra, Ronald Boellaard, Patrick M. Bossuyt, Olivier R. Busch, Hugo W. Tilanus, Maarten C.C.M. Hulshof, Ate van der Gaast, Grard A. P. Nieuwenhuijzen, Han J. Bonenkamp, John Th. M. Plukker, Miguel A. Cuesta, Fiebo J. ten Kate, Jan Pruim, Herman van Dekken, Jacques Bergman, Gerrit W. Sloof, Jan J. van Lanschot	2011	88
12	The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. PubMed ·Lia van Zuylen, Alex Sparreboom, Ate van der Gaast, M E van der Burg, V van Beurden, C.J. Bol, R. Woestenborghs, Peter Palmer, Jaap Verweij	2000	87
13	Chemotherapy as treatment of choice in extrapulmonary undifferentiated small cell carcinomas Cancer ·Ate van der Gaast, J. Verwey, Eric Prins, Ted A.W. Splinter	1990	85
14	Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein Anti-Cancer Drugs ·Alex Sparreboom, André Planting, Roxanne C. Jewell, Maria EL van der Burg, Ate van der Gaast, Peter de Bruijn, Walter J. Loos, Kees Nooter, LuWanda H Chandler, Elaine Paul, Paul Wissel, Jaap Verweij	1999	85
15	Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer Cochrane Database of Systematic Reviews ·Vincent T. Janmaat, Ewout W. Steyerberg, Ate van der Gaast, Ron H.J. Mathijssen, Marco J. Bruno, Maikel P. Peppelenbosch, Ernst J. Kuipers, Manon C.W. Spaander	2017	84
16	Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. Journal of Clinical Oncology ·Ate van der Gaast, Pieter van Hagen, Maarten C.C.M. Hulshof, D. J. Richel, Mark I. van Berge Henegouwen, Grard A. P. Nieuwenhuijzen, John Th. M. Plukker, Han J. Bonenkamp, Ewout W. Steyerberg, H.W. Tilanus, (unknown)	2010	83
17	Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy British Journal of Cancer ·M. Polée, Wim C.J. Hop, T.C. Kok, Ferry A.L.M. Eskens, M.E.L. van der Burg, Ted A.W. Splinter, Peter D. Siersema, Hugo W. Tilanus, G. Stoter, Ate van der Gaast	2003	81
18	Prophylaxis of Irinotecan-Induced Diarrhea with Neomycin and Potential Role for **UGT1A128*** Genotype Screening: A Double-Blind, Randomized, Placebo-Controlled Study The Oncologist ·Floris A. de Jong, Diederik F.S. Kehrer, Ron H.J. Mathijssen, Geert‐Jan Creemers, Peter de Bruijn, Ron H. N. van Schaik, André Planting, Ate van der Gaast, Ferry A.L.M. Eskens, J Janssen, Jan B. Ruit, Jaap Verweij, Alex Sparreboom, Maja J.A. de Jonge	2006	79
19	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Thrombospondin-1–Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Cancer Journal of Clinical Oncology ·Ronald Hoekstra, Filip De Vos, Ferry A.L.M. Eskens, Jourik A. Gietema, Ate van der Gaast, Harry J.M. Groen, Raymond A. Knight, Robert Carr, Rod Humerickhouse, Jaap Verweij, Elisabeth G.E. de Vries	2005	75
20	Lipolysis and lipid oxidation in weight-losing cancer patients and healthy subjects Metabolism ·Sonja D. Zuijdgeest-van Leeuwen, J.W.O. van den Berg, J.L.D. Wattimena, Ate van der Gaast, G.R. Swart, J.H.P. Wilson, Pieter C. Dagnelie	2000	75

About Ate van der Gaast

Ate van der Gaast is a scholar working on Surgery, Pulmonary and Respiratory Medicine, Oncology, Molecular Biology and Epidemiology, having authored 132 papers that have together received 4.7k indexed citations. Recurring topics across this work include Esophageal Cancer Research and Treatment (63 papers), Gastric Cancer Management and Outcomes (29 papers), Esophageal and GI Pathology (17 papers), Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (10 papers), Lung Cancer Diagnosis and Treatment (9 papers), Cancer Treatment and Pharmacology (8 papers) and Drug Transport and Resistance Mechanisms (7 papers). The work is most often cited by research in Surgery (2.5k citations), Oncology (1.2k citations), Pulmonary and Respiratory Medicine (1.3k citations), Cancer Research (285 citations) and Gastroenterology (70 citations). Ate van der Gaast has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include Jaap Verweij, Ewout W. Steyerberg, Mark I. van Berge Henegouwen, G. Stoter, Hugo W. Tilanus, Peter D. Siersema, Ferry A.L.M. Eskens, Pieter van Hagen, Maarten C.C.M. Hulshof and Ted A.W. Splinter. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Cancer, European Journal of Cancer, Annals of Oncology and Cancer Chemotherapy and Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Ate van der Gaast

Impact in

Papers in i

In The Last Decade

Ate van der Gaast

Ate van der Gaast's Hit Papers

Peers

Countries citing papers authored by Ate van der Gaast

Fields of papers citing papers by Ate van der Gaast

All Works

About Ate van der Gaast

Explore authors with similar magnitude of impact

Papers in